SCHEMBL16508140

SCHEMBL16508140

CCCCCCCCCCCCCCCC(=O)NC(C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NC)[C@@H](C)O

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ NPY5R Q15761 4/20 0.45
▸ NPY4R P50391 4/20 0.45
▸ NPY1R P25929 3/20 0.45
▸ RXFP1 Q9HBX9 1/20 0.43
▸ NPY2R P49146 1/20 0.42
▸ TLR2 O60603 1/20 0.41
▸ MAPK8 P45983 1/20 0.39
▸ MAPK9 P45984 1/20 0.39
▸ MAPK10 P53779 1/20 0.39
▸ HASPIN Q8TF76 1/20 0.39
▸ OPRL1 P41146 3/20 0.39
▸ ECE1 P42892 1/20 0.38
▸ GLP1R P43220 1/20 0.38
▸ MUS81 Q96NY9 1/20 0.38
▸ TFPI P10646 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16508107 1.00 NPY5R (0.45) NPY5RNPY4RNPY1RRXFP1NPY2R
SCHEMBL16508126 0.96 TLR2 (0.45) NPY5RNPY4RNPY1RRXFP1TLR2
SCHEMBL16507894 0.96 RXFP1 (0.45) NPY5RNPY4RNPY1RRXFP1MAPK8
SCHEMBL16507754 0.94 OPRL1 (0.46) RXFP1TLR2OPRL1ECE1GLP1R
SCHEMBL16508063 0.94 OPRL1 (0.46) RXFP1TLR2OPRL1ECE1GLP1R
SCHEMBL16507777 0.94 OPRL1 (0.46) RXFP1TLR2OPRL1ECE1GLP1R
SCHEMBL16508057 0.92 OPRL1 (0.46) RXFP1TLR2OPRL1ECE1GLP1R
SCHEMBL16507907 0.91 OPRL1 (0.47) RXFP1OPRL1ECE1GLP1RMUS81
SCHEMBL16508064 0.91 TFPI (0.49) RXFP1TLR2OPRL1GLP1RTFPI
SCHEMBL16507935 0.90 NPY5R (0.45) NPY5RNPY4RNPY1RRXFP1NPY2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110294738-A1 PTHR1 RECEPTOR COMPOUNDS ANTHOR THERAPEUTICS, INC. 2011-12-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294738-A1 PTHR1 RECEPTOR COMPOUNDS PTH1R, MC1R, CASR NPY5R 1478/4885NPY4R 1387/4885NPY1R 800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback